Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Date:11/7/2012

f the contingent equity rights liability following the termination of the license agreement for KRX-0401 in May 2012 and $1.6 million of non-cash compensation expense related to equity incentive grants.  The net loss for the nine months ended September 30, 2011, included license revenue of $5.0 million related to a milestone payment from the Company's Japanese partner for Zerenex (ferric citrate), Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., for their commencement, in April 2011, of a Phase 3 clinical program in Japan.

Ron Bentsur, the Company's Chief Executive Officer, said, "With the pending completion of our long-term Phase 3 study of Zerenex as a treatment for hyperphosphatemia in ESRD patients on dialysis, we look forward to reporting top-line data by year-end and anticipate the NDA filing for this indication in the first quarter of 2013.  We are also excited to have recently initiated our Phase 2 study exploring Zerenex in the non-dialysis dependent chronic kidney disease setting, which we believe represents a substantial potential additional opportunity for Zerenex."  Mr. Bentsur added, "Importantly, we believe that we have sufficient cash to take us beyond our key anticipated clinical and regulatory milestones."

The Company will host an investor conference call tomorrow, Thursday, November 8, 2012, at 8:30am EST, to discuss the Company's third quarter financial results and provide a business outlook for the remainder of 2012.In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
2. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
4. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Boston Childrens Hospital announces international genomics competition winner
7. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
8. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
9. AMRI Announces Third Quarter 2012 Results
10. Egenix, Inc. Announces New Director
11. BioRestorative Therapies Announces Stock Trading On OTC Bulletin Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the ... Annual Meeting of Stockholders on May 4, 2015 (the ... the Annual Meeting represents a change of more than ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On ... law H.R. 83, the Omnibus and Continuing Resolution ... time, made hydrocephalus a condition eligible to receive ... (CDMRP) administered by the Department of Defense (DoD). ... its allies on Capitol Hill, is celebrating this ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Coulter, Inc. (NYSE: BEC ), a leading ... and innovate complex biomedical testing, announced today it will ... at 5:00 p.m. ET to discuss the company,s third ... call, there will be a webcast presentation of accompanying ...
... 13 Osteotech, Inc. (Nasdaq: OSTE ), ... for regenerative healing, announced today that it has received ... Commission granted early termination of the Hart-Scott-Rodino waiting period ... of the merger remains subject to antitrust clearance in ...
... 13, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Beckman Coulter to host Conference Call and Webcast Presentation for Third Quarter 2010 Earnings Results on October 27, 2010 2Osteotech Announces Early Termination of HSR Waiting Period 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 3Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 4Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 5Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 6Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 7Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 8
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... water pathogens may get a lot easier and cheaper thanks ... his team. , Syed Hashsham, an associate professor in ... for Microbial Ecology, is developing a portable, hand-held device capable ... water and food. , "This device will give ...
... failure and other health conditions, blood draws and diagnostic tests ... chemical or physiologic changes silently cause damage that is not ... future a tiny device, one the size of a nickel ... monitor and detect abnormalities, and could then relay data to ...
... the thymus, where the immune system's T cells develop, if ... thousands of proteins as "self." The research confirms an ... the immune system, and not only at the sites where ... of type 1 diabetes, or the joints in rheumatoid arthritis. ...
Cached Biology News:Professors to develop hand-held pathogen testing device 2Cardiologist's 'living chip' changes science of disease monitoring 2Cardiologist's 'living chip' changes science of disease monitoring 3Cardiologist's 'living chip' changes science of disease monitoring 4Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
PMA (YPMA-1)...
Biology Products: